FOAMIX PHARMACEUTICALS LTD's ticker is FOMX and the CUSIP is M46135105. A total of 64 filers reported holding FOAMIX PHARMACEUTICALS LTD in Q4 2016. The put-call ratio across all filers is - and the average weighting 0.6%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2016 | $136,000 | – | 12,230 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| GREAT POINT PARTNERS LLC | 4,781,708 | $28,738,000 | 4.90% |
| DSC Advisors, L.P. | 1,187,604 | $7,138,000 | 4.14% |
| Opaleye Management Inc. | 960,000 | $5,769,000 | 1.85% |
| DAFNA Capital Management LLC | 352,741 | $2,120,000 | 1.14% |
| Vivo Capital, LLC | 855,000 | $5,139,000 | 1.10% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 382,838 | $2,301,000 | 0.81% |
| SENZAR ASSET MANAGEMENT, LLC | 377,397 | $2,268,000 | 0.58% |
| Sio Capital Management, LLC | 131,200 | $789,000 | 0.44% |
| Perceptive Advisors | 1,117,324 | $6,715,000 | 0.22% |
| Tekla Capital Management LLC | 930,398 | $5,592,000 | 0.22% |